CBP p300-IN-8 is a potent inhibitor of the CBP P300 family of bromodomains . CBP p300-IN-8 inhibits CBP ( IC 50 =0.01-0.1 μΜ) and BRD4 ( IC 50 =1-1000 μΜ) activity.
Thalidomide-NH-CBP/p300 ligand 2 (P-007) is a PROTAC-based compound designed to degrade CBP and p300, acting as a functional antagonist (WO2020173440).
PROTAC CBP/P300 Degrader-1 is an effective compound that degrades CBP/P300 in a potent manner. It significantly reduces cell viability in various cancer cell lines.
3BrB-PP1 is an ATP-competitive analog that exhibits specific inhibitory activity towards protein kinase. It is effective in inhibiting protein kinase with mutations in the ATP-binding pocket, specifically the mutation of Thr97 within Sty1's ATP-binding pocket.